Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.
Tongqing ZhouLingshu WangJohn MisasiAmarendra PeguYi ZhangDarcy R HarrisAdam S OliaChloe Adrienna TalanaEun Sung YangMan ChenMisook ChoeWei ShiI-Ting TengAdrian CreangaClaudia JenkinsKwanyee LeungTracy LiuErik-Stephane D StancofskiTyler StephensBaoshan ZhangYaroslav TsybovskyBarney S GrahamJohn R MascolaNancy J SullivanPeter D KwongPublished in: Science (New York, N.Y.) (2022)
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent sera are driving a search for monoclonal antibodies with potent neutralization. To provide insight into effective neutralization, we determined cryo-electron microscopy structures and evaluated receptor binding domain (RBD) antibodies for their ability to bind and neutralize B.1.1.529. Mutations altered 16% of the B.1.1.529 RBD surface, clustered on an RBD ridge overlapping the angiotensin-converting enzyme 2 (ACE2)-binding surface and reduced binding of most antibodies. Substantial inhibitory activity was retained by select monoclonal antibodies-including A23-58.1, B1-182.1, COV2-2196, S2E12, A19-46.1, S309, and LY-CoV1404-that accommodated these changes and neutralized B.1.1.529. We identified combinations of antibodies with synergistic neutralization. The analysis revealed structural mechanisms for maintenance of potent neutralization against emerging variants.